title: Evaluation of the effects of dietary n-3 fatty acid supplementation on the pharmacokinetics of doxorubicin in dogs with lymphoma.
abstract: OBJECTIVE
  To determine the effect of dietary n-3 fatty acids on the pharmacokinetics of doxorubicin in dogs with lymphoma.
  
  
  METHODS
  23 dogs with lymphoma in stages IIIa, IVa, and Va.
  
  
  METHODS
  Dogs receiving doxorubicin chemotherapy were randomly allocated to receive food with a high (test group) or low (control group) content of n-3 fatty acids. Serum doxorubicin and doxorubicinol concentrations were measured via high-performance liquid chromatography before and 6 to 9 weeks after initiation of the diets. Lymph node concentrations of doxorubicin were assessed 6 hours after the initial treatment. Dogs' body composition was assessed by means of dual-energy x-ray absorptiometry scans.
  
  
  RESULTS
  No significant differences in doxorubicin pharmacokinetics were detected between treatment groups. Significant differences existed between the first and second sampling times among all dogs for area under the curve, maximum serum concentration, and clearance. Differences in body composition did not affect measured pharmacokinetic variables. The terminal elimination half-life was longer in dogs in which a long-term remission was achieved than in dogs that did not have remission.
  
  
  CONCLUSIONS
  Dietary supplementation of n-3 fatty acids is common in veterinary patients with neoplasia, but supplementation did not affect doxorubicin pharmacokinetics in this population of dogs. Explanations for the beneficial effects of n-3 fatty acids other than alterations in the pharmacokinetics of chemotherapy drugs should be investigated. Dogs may metabolize drugs differently prior to remission of lymphoma than when in remission. The pharmacokinetics of doxorubicin at the time of the first administration may predict response to treatment.
authors.affiliation: Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
authors.forename: Kim A
authors.initials: KA
authors.lastname: Selting
authors.forename: Gregory K
authors.initials: GK
authors.lastname: Ogilvie
authors.forename: Daniel L
authors.initials: DL
authors.lastname: Gustafson
authors.forename: Michael E
authors.initials: ME
authors.lastname: Long
authors.forename: Susan E
authors.initials: SE
authors.lastname: Lana
authors.forename: Judy A
authors.initials: JA
authors.lastname: Walton
authors.forename: Rodney A
authors.initials: RA
authors.lastname: Hansen
authors.forename: A Simon
authors.initials: AS
authors.lastname: Turner
authors.forename: Irene
authors.initials: I
authors.lastname: Laible
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Fettman
mesh_terms: D000818:Animals; D002851:Chromatography, High Pressure Liquid; D019587:Dietary Supplements; D004283:Dog Diseases / Q000188:drug therapy / Q000378:metabolism*; D004285:Dogs; D004317:Doxorubicin / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D015525:Fatty Acids, Omega-3 / Q000378:metabolism* / Q000494:pharmacology; D006207:Half-Life; D008223:Lymphoma / Q000188:drug therapy / Q000378:metabolism / Q000662:veterinary*; D013997:Time Factors
chemical_list: D015525:Fatty Acids, Omega-3; D004317:Doxorubicin